Hepion Pharmaceuticals reports developments around its transition into precision diagnostics, with a focus on blood-based tests for hepatocellular carcinoma and other disease areas. Company updates include the ctRNA biomarker assay licensed for early diagnosis and surveillance of HCC, the mSEPT9 PCR-based assay for liver cancer detection, and diagnostic test categories covering celiac disease, respiratory multiplex testing, H. pylori, and HCC.
Hepion news also covers public-company status changes and capital actions, including OTCQB trading, reverse stock split activity, Nasdaq delisting developments, leadership changes, stockholder voting matters, and the completed sale of rencofilstat-related patent assets, knowhow, clinical trial data, and drug product.
Hepion Pharmaceuticals (NASDAQ: HEPA) has announced the termination of its merger agreement with Pharma Two B . The merger agreement, which was initially entered into on July 19, 2024, has been mutually terminated with no termination fees required from either party. As a result, Hepion has cancelled its special stockholders meeting scheduled for December 12, 2024, and withdrawn the proposals outlined in its Definitive Proxy Statement filed with the SEC on November 8, 2024.
Hepion Pharmaceuticals (HEPA) has issued a letter to shareholders urging support for its proposed merger with Pharma Two B at the upcoming Special Meeting on December 12, 2024. The company's board unanimously recommends the merger after reviewing strategic alternatives, citing financial challenges and inability to fund clinical development. The merger would allow shareholders to participate in Pharma Two B's late-stage Parkinson's Disease treatment, P2B001. If the merger fails to receive shareholder approval, Hepion warns of potential Nasdaq delisting and bankruptcy risks due to financial resources. While Pharma Two B doesn't plan to advance Hepion's drug pipeline, Hepion remains committed to attempting to monetize its assets for shareholder benefit.
Pharma Two B and Hepion Pharmaceuticals (NASDAQ: HEPA) announced that the SEC has declared effective their merger registration statement on Form F-4. The merger, announced on July 22, 2024, will combine Pharma Two B's P2B001 Parkinson's Disease treatment candidate with Hepion's liver disease portfolio. The transaction is expected to close in Q4 2024, subject to stockholder approvals and other conditions. A special stockholder meeting is scheduled for December 12, 2024, at 9:00 AM ET via webcast. Upon closing, the combined entity will operate as Pharma Two B and trade under the symbol 'PHTB'.
Pharma Two B and Hepion Pharmaceuticals (Nasdaq: HEPA) have filed a registration statement on Form F-4 with the SEC for their proposed merger. The filing contains a proxy statement/prospectus detailing the transaction announced on July 22, 2024. Pharma Two B, developing P2B001 for Parkinson's Disease, aims to go public on Nasdaq through this merger with Hepion, which has been developing treatments for liver diseases including NASH and HCC.
The merger, approved by both companies' boards, is expected to close in Q4 2024, subject to stockholder and regulatory approvals. Post-merger, the combined entity will operate as Pharma Two B and trade under the ticker symbol "PHTB". The transaction is supported by financial advisors A.G.P./Alliance Global Partners for Hepion and Laidlaw & Company (UK) for Pharma Two B, along with respective legal advisors.
Pharma Two B, a late-stage clinical company developing P2B001 for Parkinson's Disease, has announced plans to go public through a merger with Hepion Pharmaceuticals (Nasdaq: HEPA). The deal includes a concurrent $11.5 million private placement. Post-merger, Pharma Two B shareholders will own approximately 44.5% of the combined company, Hepion shareholders 7.8%, and new investors 47.7%. The company plans to submit an NDA for P2B001 in the first half of 2026. Hepion has also secured a $2.9 million Senior Unsecured Note from institutional investors. The merger is expected to close in Q4 2024, subject to regulatory and shareholder approvals.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.